This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Drugs

DHS Deadline, NRG Earnings: What to Watch on Wall Street Feb. 27

  • Tickers in this article:
  • NRG
  • ISIS

Friday, February 27th is the funding deadline for the Department of Homeland Security.

02/26/15 - 08:00 PM EST

Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

02/27/15 - 06:00 AM EST

Try Jim Cramer's Action Alerts PLUS
GlaxoSmithKlein's Diet Pill Alli Back in Stores After Recall

GlaxoSmithKlein's Diet Pill Alli Back in Stores After Recall

  • Tickers in this article:
  • GSK

GlaxoSmithKline's diet pill, alli, is now back in most U.S. stores.

02/25/15 - 09:48 AM EST

Ampio Too Busy to Tell Investors Results of Eye Drug Study

Ampio Too Busy to Tell Investors Results of Eye Drug Study

  • Tickers in this article:
  • AMPE

Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.

02/25/15 - 07:55 AM EST

Jim Cramer on Valeant: This Is an Amazing Pharmaceutical Firm

Jim Cramer on Valeant: This Is an Amazing Pharmaceutical Firm

It is no pipe dream that the stock could trade to $240

02/24/15 - 11:39 AM EST

What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results

What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results

  • Tickers in this article:
  • VRTX

Later this quarter, Vertex Pharmaceuticals will be disclosing new clinical data on its next cystic fibrosis drug, VX-661. Here's a preview.

02/23/15 - 11:06 AM EST

Valeant Pharmaceuticals to Acquire Salix Pharma for $14.5 Billion

Valeant Pharmaceuticals to Acquire Salix Pharma for $14.5 Billion

Laval, Canada-based Valeant Pharmaceuticals announced on Sunday that it would acquire Raleigh, North Carolina-based Salix Pharmaceuticals for an enterprise value of $14.5 billion.

02/23/15 - 02:31 PM EST

Cramer: Valeant's Not Done Going Higher, Buy on Salix Acquisition

Cramer: Valeant's Not Done Going Higher, Buy on Salix Acquisition

Jim Cramer weighs-in on Valeant Pharmaceuticals' $10 billion acquisition of Salix.

02/23/15 - 01:43 PM EST

Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal

Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal

Following last year's failed attempt to purchase Allergan, the Canadian pharmaceutical giant continues its acquisition strategy with its latest deal.

02/23/15 - 12:03 PM EST

Valeant Surges on Salix Acquisition: What Wall Street's Saying

Valeant Surges on Salix Acquisition: What Wall Street's Saying

  • Tickers in this article:
  • SLXP
  • VRX

Investors are cheering for Valeant Pharmaceutical's planned $14.5 billion acquisition of Salix Pharmaceuticals, but Salix shareholders were hoping for more.

02/23/15 - 11:51 AM EST

Valent & Salix, 3M & Polypore Deals Can't Stop Stocks From Slipping

Valent & Salix, 3M & Polypore Deals Can't Stop Stocks From Slipping

U.S. stocks slipped on Wall Street but werestill near record highs at Monday's midday trading.

02/23/15 - 11:47 AM EST

Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies

Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies

The pharma giant is making an upfront payment of $800 million and committing to up to $450 million more in milestone payments.

02/23/15 - 11:14 AM EST

Stocks Start Week at Record Highs, HSBC Under Fire for Tax Issues

Stocks Start Week at Record Highs, HSBC Under Fire for Tax Issues

Wall Street starts the week with a look at Existing Home Sales, President Obama address and continued focus on Greece as it gets a last minute loan extension.

02/23/15 - 07:50 AM EST

Valeant Agrees to Buy Salix Pharma for $14.5 Billion in Cash

Valeant Agrees to Buy Salix Pharma for $14.5 Billion in Cash

  • Tickers in this article:
  • VRX
  • SLXP

Canada's Valeant Pharma agreed to buy Salix Pharma in cash deal valued at about $14.5 billion, the companies said Sunday.

02/22/15 - 08:37 PM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs